LeanLife Provides Product Approvals Update
VANCOUVER, British Columbia, June 25, 2018 (GLOBE NEWSWIRE) -- “LeanLife Health Inc. (the “Company” or “LeanLife”) (CSE:LLP) announced today that it has retained external consultants to assist with ensuring that all of its Omega 3 products meet relevant food safety requirements and designations in Canada and the United States. The engagement is in addition to, and will augment, the Company’s effort to obtain government authorization for production of Omega 3 products at its Canadian manufacturing facility.
LeanLife continues to prepare for initial production at the 4,000 sq. ft. facility it leased in Vancouver earlier this year. The plant will be responsible for the manufacture of all LeanLife Omega 3 products, including ingredients for making and/or fortifying commercial foods such as bread, noodles, juices, yogurt and cheese.
“I am pleased with the progress LeanLife has made toward obtaining the permits and approvals needed to manufacture our products, as well as to meet the standards set forth by large commercial users of Omega 3 ingredients,” commented Stan Lis, Chief Executive Officer of LeanLife Health. “The addition of third-party consultants to this effort should enable us to obtain some of the approvals sooner, which would obviously be positive for our go-to-market strategy.”
About LeanLife Health and the Omega 3 Market
LeanLife Health’s products are extracted from flax seeds, a plentiful and non-animal source of Omega 3. The products can be used as nutraceuticals or as additives/ingredients in foods such as bread, noodles, cheese, yogurt, juice and milk. LeanLife Health’s Omega 3 formulations contain no cholesterol and, following receipt of all government and industry approvals, will be marketed in oil, emulsion and powder forms.
The global Omega 3 market is expected to reach US$7.32 billion by 2020, according to a report by Grand View Research, Inc.
For more information, please contact:
Stan Lis, CEO
Tel: 604 764-0518
E-mail: slis@leanlifehealth.com
Forward Looking Information
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control including, the Company's ability to compete with large food companies; sales of any potential products developed will be profitable; the ability to complete sales under the sales agreement. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
THE CSE HAS NEITHER APPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Aptinyx (Nasdaq: APTX) Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder (PTSD)
